Financial Results
Shree Pacetronix Publishes Q2 FY27 Results Clippings
Shree Pacetronix submitted newspaper clippings of its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
1
Neutral
6
Bullish
7
Bearish
20
Neutral
6
Bullish
20
Bearish
19
Neutral
0
Bullish
13
Bearish
19
Neutral
0
Bullish
13
Bearish
19
Neutral
0
Bullish
13
Bearish
19
Neutral
0
Bullish
13
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Healthcare Equipment & Supplies
Medical Equipment & Supplies
66 Cr
High Risk
21.5
60.5
0.1
3.3
279.00
90.00
Sales CAGR
Profit CAGR
ROE
ROCE
Shree Pacetronix Ltd (SHREEPAC) is currently trading at 169.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Shree Pacetronix Limited manufactures and exports implantable pacemakers from its Pithampur, Madhya Pradesh facility with an installed capacity of 4,800 pacemakers per annum, focusing exclusively on life‑saving cardiac devices and catering to both domestic and export markets with a small consolidated subsidiary, Shree Coratomic Limited. Financial performance improved materially year‑over‑year: nine months revenue rose to Rs.1,626.95 lakhs from Rs.1,252.33 lakhs, and nine months profit after tax jumped to Rs.204.69 lakhs versus Rs.28.75 lakhs in the prior year, indicating stronger demand, better operational leverage, and improved margins in the ongoing financial period. Quarterly volatility is evident: revenue for Q3 FY26 declined to Rs.433.46 lakhs from Rs.659.19 lakhs in the prior quarter and profit before tax fell sharply to Rs.16.34 lakhs, reflecting seasonality, order timing, inventory movements, or one‑off factors that management will need to address to stabilise quarter‑to‑quarter performance. Management has approved a significant promoter‑led preferential allotment totalling Rs.18.26 crore in potential equity; 25% of proceeds received upfront, convertible within 18 months, which provides immediate liquidity headroom and a runway to fund working capital, R&D initiatives such as longer‑lasting batteries and remote monitoring, or modest capacity and product development investments. The group remains single‑segment focused on life‑saving devices with marginal subsidiary revenues, regulated product development needs, and R&D emphasis on battery longevity, MRI‑safe and leadless pacemaker features — positioning Shree Pacetronix Limited in a technically specialised, highly regulated medtech niche with high clinical importance but capital‑light incremental manufacturing requirements.
Over the past 52 weeks, Shree Pacetronix Ltd has traded between a low of ₹90.00 and a high of ₹279.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Shree Pacetronix Ltd has a market capitalization of approximately 65.58. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Shree Pacetronix Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.50 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 65.58 Cr, Shree Pacetronix Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Shree Pacetronix Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Shree Pacetronix Ltd is 21.50. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Shree Pacetronix reported a Rs 1.75 crore net reduction in short-term borrowings during the half-year ended September 30, 2026. Current borrowings on the balance sheet were Rs 53.32 lakh at September 30, compared with Rs 2.29 crore at March 31, 2026.
Shree Pacetronix reported standalone profit after tax of Rs 1.11 crore for the quarter ended 30 September 2026. This compared with Rs 1.32 crore in the September 2025 quarter, a year-on-year decline of 15.55%.
Shree Pacetronix reported consolidated profit after tax of ₹1.12 crore for Q2 FY27. Standalone profit after tax was ₹1.11 crore for the quarter ended September 30, 2026.
Financial Results
Shree Pacetronix submitted newspaper clippings of its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
Regulatory/Compliance Filing
Shree Pacetronix confirmed no deviation or variation in the use of Rs. 243.48 lakh raised through a preferential issue for the quarter and half year ended September 30, 2026.
Financial Results
Shree Pacetronix submitted unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026, along with limited review reports carrying unmodified conclusions.
Financial Results
Shree Pacetronix approved unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026, along with unmodified limited review reports.
